The U.S. Food and Drug Administration (FDA) issued a formal written request to Shelhigh, Inc. to recall all of its medical devices remaining in the marketplace, including hospital inventories, because of sterility concerns.
The U.S. Food and Drug Administration (FDA) cleared for marketing the first respirators that can help reduce the user’s exposure to airborne germs during a public health medical emergency, such as an influenza pandemic.
Columbia researchers have uncovered a critical age when many inner city children become overweight or obese: between the ages of 1 and 3 years old.
When emergency teams are well informed and governments can coordinate their efforts, lives and property can be saved. The Health Early Warning System, a project supported by ESA, is intended to bring this benefit to Europe.
A diet high in whole grain foods is associated with a significantly lower risk of developing cardiovascular disease, including heart disease and stroke, according to an analysis conducted by researchers at Wake Forest University School of Medicine.
Data released today show that MR-guided focused ultrasound (MRgFUS) is a more effective option for a broader population of uterine fibroid sufferers.
A new study in mice raises a tantalizing possibility — that humans may one day be able to eat any kind of fat they want without raising their risk of heart disease.
There is very low risk to human health from consuming meat from hogs and chickens known to have been fed animal feed supplemented with pet food scraps that contained melamine and melamine-related compounds, according to an assessment conducted by scientists from five federal agencies.
Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced that it received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Bayer Pharmaceuticals Corporation’s Nimotop(R) (nimodipine) Capsules, 30 mg.
Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced that the Company has received two U.S. Food and Drug Administration (FDA) approvals related to its ENJUVIA(TM) (synthetic conjugated estrogens, B) product.